Skip to main content
Equibles
BSX logo

BSX · Boston Scientific Corp

Track BSX — free

Use BSX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$47.35 -0.45 (-0.94%)
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$69.27B
Shares
1.45B

BSX metrics

87 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$47.80
Market cap
$69.27B

Price action

19 metrics
Price change (1W)
+2.0%
Price change (30D)
-5.3%
Price change (3M)
-1.5%
Price change (6M)
-33.0%
Price change (YTD)
-49.9%
Price change (1Y)
-55.4%
Trailing year
Price change (5Y)
+6.4%
52-week high
$108.14
52-week low
$42.63
Change from 52-week high
-55.8%
Change from 52-week low
+12.1%
Annualized volatility
37.4%
Beta
0.2
RSI (14D)
47.7
Price vs SMA 50
+1.9%
Price vs SMA 200
-28.4%
Avg volume (3M)
19.78M
Relative volume
0.8
Average dollar volume
$923.63M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
1.45B

Valuation

12 metrics
P / E (TTM)
19.4
Trailing earnings · reciprocal yield 5.2%
PEG ratio
1.3
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.3×
reciprocal yield 30.3%
P / book
2.8
reciprocal yield 36.0%
FCF yield
5.2%
TTM · current market cap
Buyback yield
0.0%
P / FCF
19.1
reciprocal yield 5.2%
P / operating cash flow
15.3
reciprocal yield 6.5%
Earnings yield
5.3%

Historical valuation

8 metrics
P / E historical average (3Y)
58.3×
reciprocal yield 1.7%
P / E historical average (5Y)
68.6×
reciprocal yield 1.5%
EV / revenue historical average (3Y)
7.3×
reciprocal yield 13.8%
EV / revenue historical average (5Y)
6.7×
reciprocal yield 14.9%
EV / EBIT historical average (3Y)
44.1×
reciprocal yield 2.3%
EV / EBIT historical average (5Y)
51.6×
reciprocal yield 1.9%
EV / EBITDA historical average (3Y)
29.3×
reciprocal yield 3.4%
EV / EBITDA historical average (5Y)
30.0×
reciprocal yield 3.3%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-10-28
Last earnings
2026-07-29

Profitability

9 metrics
Gross margin
69.9%
Operating margin
19.8%
Trailing 12 months
Net margin
17.5%
Gross profit (TTM)
$14.68B
Operating profit (TTM)
$4.15B
Net income (TTM)
$3.67B
Trailing 12 months
Diluted EPS (TTM)
$2.47
FCF margin
17.3%
Effective tax rate
5.0%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$7.44

Growth

11 metrics
Revenue growth YoY
+7.5%
Year over year
Net income growth YoY
+13.8%
Revenue (TTM)
$21.00B
Trailing 12 months
EPS growth YoY
+15.1%
Shares change YoY
-1.3%
Year over year · fewer shares
Revenue CAGR (3Y)
+16.5%
Revenue CAGR (5Y)
+15.2%
EPS CAGR (3Y)
+62.8%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+57.4%
FCF CAGR (5Y)
+26.4%

Quality

14 metrics
Return on equity
14.7%
Return on assets
8.1%
Debt / equity
—
Current ratio
1.2
EBITDA (TTM)
$5.57B
Free cash flow (TTM)
$3.62B
Quick ratio
0.7
Interest coverage
11.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$539.00M
Total assets
$45.22B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$4.53B
Capital expenditures (TTM)
$904.00M
R&D (TTM)
$2.15B
SG&A (TTM)
$7.16B
Stock compensation (TTM)
$320.00M
R&D / revenue
10.3%
Stock compensation / revenue
1.5%

Ownership (13F)

3 metrics
13F filers
1,485
13F filer change QoQ
-200
Institutional ownership
95.7%

Short interest

3 metrics
Short interest
1.9%
Latest settlement · 1.6 days to cover
Days to cover
1.6d
Short-squeeze score
53 / 100

Insider activity

2 metrics
Net insider buying (90D)
$9.49M
Insider-sentiment score
91 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 885725 CUSIP 101137107 13F (30d) 775 filings 722 filers Visit website Investor relations